These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 787953)

  • 1. Pharmacokinetics of propranolol: a review.
    Shand DG
    Postgrad Med J; 1976; 52 Suppl 4():22-25. PubMed ID: 787953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of route of administration and blood flow on hepatic drug elimination.
    Shand DG; Kornhauser DM; Wilkinson GR
    J Pharmacol Exp Ther; 1975 Dec; 195(3):424-32. PubMed ID: 1195129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics.
    Vu VT; Bai SA; Abramson FP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):55-61. PubMed ID: 6848749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of phenobarbital with propranolol in the dog. 3. Beta blockade.
    Bai SA; Abramson FP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):62-7. PubMed ID: 6129320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of propranolol isomers and their relationships with beta adrenoceptor blocking activity in rabbits administered with dl-propranolol.
    Kawashima K; Ishikawa H
    J Pharmacol Exp Ther; 1980 Jun; 213(3):628-31. PubMed ID: 6110769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
    Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
    Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of experimental renal failure on the disposition kinetics of l-propranolol in rats.
    Terao N; Shen DD
    J Pharmacol Exp Ther; 1983 Nov; 227(2):295-301. PubMed ID: 6631714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of portasystemic anastomoses in childhood on propranolol pharmacokinetics].
    Cario WR; Glende M; Lampe D; Buchali K; Bürger K; Grossmann P; Huth M; Rüstow B; Zimmermann HB
    Schweiz Med Wochenschr; 1981 Jul; 111(29):1088-93. PubMed ID: 7268362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of drug concentration measurements in studies of the therapeutic response to propranolol.
    Chidsey C; Pine M; Favrot L; Smith S; Leonetti G; Morselli P; Zanchetti A
    Postgrad Med J; 1976; 52 Suppl 4():26-32. PubMed ID: 967771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans.
    Kiriyama A; Honbo A; Iga K
    Int J Pharm; 2008 Feb; 349(1-2):53-60. PubMed ID: 17765415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of propranolol.
    Routledge PA; Shand DG
    Clin Pharmacokinet; 1979; 4(2):73-90. PubMed ID: 378502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Important factors determining human distribution and elimination of diazepam].
    Klotz U
    Fortschr Med; 1977 Aug; 95(32):1958-64. PubMed ID: 334648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing.
    Wells PG; Feely J; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1983 May; 33(5):603-8. PubMed ID: 6839632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of ageing on the hepatic clearance of propranolol.
    Castleden CM; George CF
    Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent presystemic elimination of propranolol due to hepatic first-pass metabolism in rats.
    Iwamoto K; Watanabe J
    J Pharm Pharmacol; 1985 Nov; 37(11):826-8. PubMed ID: 2867168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis and disposition of low dose oral propranolol.
    MacKichan JJ; Pyszczynski DR; Jusko WJ
    Res Commun Chem Pathol Pharmacol; 1978 Jun; 20(3):531-8. PubMed ID: 674830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.